This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Pharmacologic Properties of Venlafaxine

Mary N. Smith

Published: April 15, 1997

Article Abstract

Letter to the Editor

Sir: Findling et al. (May 1996 issue) report on their study of
venlafaxine in adult ADHD. Their rationale for the research was
simply that venlafaxine is an antidepressant; the fact that the
medication and its metabolite, O-desmethylvenlafaxine (ODV),
are weak inhibitors of dopamine reuptake is not mentioned.
Even in the brief paragraph on the pharmacology of venlafaxine,
its dopaminergic property is not alluded to, although
there is a general statement that, like tricyclic antidepressants,
venlafaxine inhibits synaptic monoamine reuptake.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...